Can Genetic Diseases Be Treated with IVF in Hong Kong? Conditions and Process for PGT Screening in Third-Generation IVF

AI Reference Summary

Can carriers or patients with genetic diseases block the transmission of genetic diseases to the next generation through Hong Kong IVF technology? The answer is: yes, but with clear technical boundaries and strict applicable conditions. Hong Kong's third-generation IVF (PGT) technology can perform genetic screening at the embryo level, selecting embryos that do not carry the pathogenic gene for transfer, thereby blocking the familial transmission of genetic diseases. However, this technology is not applicable to all genetic diseases. Whether it can be carried out depends on whether the pathogenic gene is clear, whether the mutation site is known, whether there is a feasible detection method, and whether it meets the regulatory requirements of the Hong Kong Council on Human Reproductive Technology.

Reproductive Doctors' Professional Judgment on IVF for Genetic Diseases

From a clinical reproductive medicine perspective, the core value of choosing Hong Kong IVF for families with genetic diseases lies in the precision of PGT technology. PGT-M (Monogenic Disease Screening) requires that the pathogenic mutation has been clearly identified through genetic testing in the proband or both partners, and that the mutation can be reliably detected at the laboratory level. If the pathogenic gene has not yet been cloned, or the mutation type is a complex variation such as dynamic mutation or large fragment deletion, establishing a detection plan will take longer, or may even be impossible. Clinically, doctors will first evaluate the inheritance pattern of the genetic disease (autosomal dominant, recessive, X-linked, or mitochondrial inheritance) and then determine the feasibility of PGT.

For chromosomal structural abnormalities (such as balanced translocation, Robertsonian translocation, inversion, etc.), PGT-SR can screen for embryos with normal or balanced chromosome copy numbers, reducing the risk of miscarriage and birth defects. However, it should be noted that PGT-SR cannot distinguish between balanced translocation carriers and completely normal karyotypes, which needs to be fully explained to patients during genetic counseling. During consultation, doctors will require both partners to provide complete genetic diagnostic data, including genetic testing reports, chromosome karyotype analysis, family genetic pedigrees, etc., and formulate a personalized PGT plan based on this.

Time Planning from Initial Consultation to Embryo Transfer

The overall cycle for going to Hong Kong for third-generation IVF for genetic diseases is usually 4 to 6 months. The specific duration is affected by factors such as the complexity of the test, the hospital's schedule, and embryo development. The following are the regular time points:

If family linkage analysis is required (e.g., the mutation site is unclear or haplotype construction is needed), the time will be extended by 3 to 5 weeks. In addition, some hospitals require centralized submission or have queues for PGT testing, so the actual waiting time may fluctuate. It is recommended to allow sufficient time buffer to avoid delays in the overall plan due to testing delays.

Key Details Easily Overlooked

Confirmation of the mutation site is a prerequisite. Many families with genetic diseases think that PGT can be done as long as there is a diagnosis of the genetic disease, but in reality, the laboratory needs to know the specific gene mutation site to design the detection probe. If only a clinical diagnosis has been made without genetic testing, or the genetic test report only states "suspected pathogenic" without specifying the mutation, genetic confirmation must be completed first. This step is often overlooked, leading to the inability to start the PGT process after arriving in Hong Kong.

Timing of family sample collection. For some genetic diseases, especially recessive inheritance or de novo mutations, linkage analysis of parents, the proband, and even larger family members may be necessary. If family members are scattered in different cities or are unwilling to provide samples, it will directly affect the establishment of the testing plan. It is recommended to coordinate the informed consent and sample collection of family members in advance before deciding to go to Hong Kong.

Validity period and format of test reports. Reproductive centers in Hong Kong usually require genetic test reports to be issued by a qualified laboratory. The report must indicate the testing method, the HGVS nomenclature of the mutation site, and the pathogenicity rating (ACMG standards). If the report format is incomplete or the test was done too long ago (more than 2 years), retesting or supplementary verification may be required.

Standard Process for Third-Generation IVF Screening for Genetic Diseases in Hong Kong

The entire process is divided into four main stages, each with clear medical and administrative steps:

• Stage 1: Genetic Access Assessment. The patient submits the genetic disease diagnosis certificate, genetic test report, chromosome karyotype analysis (if available), and family genetic pedigree to the Hong Kong reproductive center. The hospital's genetic counselor and clinical geneticist review the information to determine whether PGT conditions are met and formulate a preliminary testing strategy.
• Stage 2: Establishment of PGT Testing Plan. For PGT-M, the laboratory needs to design specific primers or probes based on the mutation site and conduct pre-experimental verification using family samples. For PGT-SR, the breakpoint region of the chromosomal rearrangement needs to be confirmed, and an appropriate SNP chip or NGS platform is selected. This stage requires patients to provide blood samples (from both partners and the proband/family members).
• Stage 3: IVF and Embryo Biopsy. The woman undergoes ovarian stimulation treatment. After egg retrieval, intracytoplasmic sperm injection (ICSI) is performed. Embryos are cultured to the blastocyst stage on day 5-6, and 3-5 cells are biopsied from the trophectoderm for genetic analysis. The biopsied blastocysts are cryopreserved pending genetic test results.
• Stage 4: Embryo Selection and Transfer. After the genetic test report is issued, the doctor selects embryos that are chromosomally normal and do not carry the pathogenic gene for frozen-thawed transfer based on the results. A blood test is performed 12-14 days after transfer to confirm pregnancy. Subsequent prenatal diagnosis (amniocentesis or chorionic villus sampling) is still required to ultimately confirm the genetic status of the fetus.

Frequently Asked Questions about IVF for Genetic Diseases

Q1: Can all genetic diseases be screened by Hong Kong PGT?

No. PGT-M requires that the pathogenic gene is clear, the mutation site is known, and the laboratory has a mature testing plan. For some rare genetic diseases, diseases where the gene locus has not yet been cloned, or mutation types such as trinucleotide repeat dynamic mutations (e.g., Huntington's disease), the testing plan is more complex and requires case-by-case evaluation. Due to the difficulty in accurately assessing heteroplasmy levels through embryo biopsy, the application of PGT for mitochondrial genetic diseases is currently very limited.

Q2: How accurate is PGT testing?

In routine PGT-M, the detection accuracy can reach 95% to 99%, but there are technical risks such as allele dropout (ADO), mosaicism, and sample contamination. Therefore, prenatal diagnosis (amniocentesis or chorionic villus sampling) is recommended for all PGT pregnancies for verification, and PGT results alone should not be used as the final diagnostic basis.

Q3: What documents are needed for IVF for genetic diseases in Hong Kong?

Both partners need to provide valid passports or Mainland Travel Permits for Hong Kong and Macau, as well as mainland Chinese ID cards and marriage certificates. Hong Kong hospitals require the establishment of a complete medical file. Some centers may require infectious disease screening reports (Hepatitis B, Hepatitis C, HIV, Syphilis, etc.) from within the last 3 months.

Q4: If both partners are carriers of a recessive genetic disease, can PGT completely prevent the birth of an affected child?

PGT can screen for embryos that are completely normal (not carrying the pathogenic gene) and carriers (carrying one mutation but usually not developing the disease), thereby blocking the transfer of affected embryos. However, it is important to note that PGT cannot repair the genetic defect in the embryo, nor can it change the genetic law of a 25% probability of disease in natural conception; it simply selects unaffected embryos for transfer. For autosomal recessive genetic diseases, carrier embryos themselves do not develop the disease. Whether to transfer them is a decision for the family to make after genetic counseling.

Q5: How long does PGT testing take?

From embryo biopsy to the issuance of the genetic test report, it usually takes 3 to 5 weeks. If the testing plan needs to be redesigned or verified, the time may be extended to 6 to 8 weeks. Some hospitals offer expedited services, but the cost increases accordingly.

Key Examination Indicators and Report Interpretation

IVF for genetic diseases involves multiple levels of testing. The following are the most core indicators and their clinical significance:

When interpreting PGT reports, attention should be paid to the criteria for determining "transferable embryos": it usually requires normal (or balanced) chromosome copy number and no pathogenic gene mutation. Some embryos may be mosaic (partially normal cells, partially abnormal cells). Whether to transfer depends on the mosaic ratio, the type of genetic disease, and clinical experience.

Differences in PGT Capabilities Among Hong Kong Reproductive Centers

There are currently more than ten reproductive centers in Hong Kong licensed by the Hong Kong Council on Human Reproductive Technology, but there are differences in their capabilities and experience in the PGT field:

When choosing a hospital, in addition to focusing on the PGT technology platform, it is also necessary to understand whether the center has testing experience matching your specific type of genetic disease. Some centers have mature testing plans for specific genetic diseases (such as thalassemia, spinal muscular atrophy), while extremely rare mutations may require longer preparation time. It is recommended to ask the hospital to clearly inform you of the timeline for establishing the testing plan and the testing results of similar cases in the past during the initial consultation.